Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 11, 2011Journal of Clinical OncologyOpen Access

Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

APAnimesh PardananiUppsala UniversityJGJason GotlibOntario Institute for Cancer ResearchCJCatriona JamiesonLa Jolla Alcohol Research

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Pardanani et al. (2011) studied this question.

synapsesocial.com/papers/6a0f94965725bbd5cc5fe092https://doi.org/10.1200/jco.2010.32.8021
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Myelofibrosis with Myeloid Metaplasia2000 · 747 citations
  2. 2Somatic Mutations ofIDH1andIDH2in the Leukemic Transformation of Myeloproliferative Neoplasms2010 · 289 citations
  3. 3Mutation in TET2 in Myeloid Cancers2009 · 1,782 citations
  4. 4Clinical correlates of JAK2V617F allele burden in essential thrombocythemia2007 · 157 citations
  5. 5Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance2007 · 748 citations